Question to the Department of Health and Social Care:

To ask Her Majesty's Government whether Kaftrio is available to cystic fibrosis patients in England; if not, why not; if it is available to such patients, whether there are any restrictions on that drug's availability; and if so, why.

Kaftrio is available to National Health Service patients in England in line with its license through an interim access deal negotiated between NHS England and NHS Improvement and Vertex, the drug manufacturer. This deal will last for four years and means that eligible NHS patients are among the first in Europe to benefit from access to Kaftrio.

As part of this deal, NHS England and NHS Improvement committed to expanding patient access to Kaftrio to cover any future license extensions by the European Medicines Agency.